# Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: INSM
Company: Insmed
Source: Insmed
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.insmed.com
## Summary

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious...

## Article Body
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

, / PRNewswire / -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, on May 29, 2026, the employees received 97,091 restricted stock units and options to purchase an aggregate 12,850 shares of Insmed common stock at an exercise price of $106.91 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The restricted stock units have a four-year vesting schedule, with 25% of the shares underlying each restricted stock unit grant vesting on each anniversary of the first day of the month immediately following the grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the first day of the month immediately following the grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary thereof, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn , Instagram , YouTube , and X .

Contact:

Investors:

Bryan Dunn Vice President, Investor Relations (646) 812-4030 investor.relations@insmed.com

Media:

Claire Mulhearn Vice President, Corporate Communications (862) 842-6819 media@insmed.com

SOURCE Insmed Incorporated
## Recent Company News
- 2026-07-16 11:00 EST — [Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension](https://biopharmsignal.com/news/INSM/insmed-announces-positive-12-month-data-from-the-ongoing-open-label-extension-st-7880862e) — Source: Insmed
- 2026-06-25 13:46 EST — [Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory](https://biopharmsignal.com/news/INSM/insmed-appoints-samuele-butera-as-senior-vice-president-general-manager-global-respiratory) — Source: Insmed
- 2026-06-25 13:46 EST — [Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/INSM/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Insmed
- 2026-06-25 13:46 EST — [Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference](https://biopharmsignal.com/news/INSM/insmed-to-present-at-the-2026-goldman-sachs-annual-global-healthcare-conference) — Source: Insmed
- 2026-06-25 13:46 EST — [Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/INSM/insmed-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Insmed
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)